NDC 57664-088 – Lisdexamfetamine Dimesylate
Lisdexamfetamine Dimesylate 60 mg/1 · Tablet, Chewable · Oral
Product NDC57664-088
Product details
- Brand name
- Lisdexamfetamine Dimesylate
- Generic name
- Lisdexamfetamine Dimesylate
- Labeler
- Sun Pharmaceutical Industries, Inc.
- Dosage form
- Tablet, Chewable
- Route
- Oral
- Marketing category
- ANDA · ANDA214134
- Marketed since
- August 25, 2023
- Listing expires
- December 31, 2027
- Pharmacologic class
- Central Nervous System Stimulant
Active ingredients
- Lisdexamfetamine Dimesylate 60 mg/1
Uses, dosage, side effects and warnings for Lisdexamfetamine dimesylate →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 57664-088-88 | 100 TABLET, CHEWABLE in 1 BOTTLE (57664-088-88) | Aug 25, 2023 |
Recalls mentioning this NDC
- D-0148-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0150-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0145-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0146-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0144-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0149-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0147-2026 Nov 5, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate… - D-0516-2025 Jul 23, 2025 · Class II
Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).
Other Lisdexamfetamine dimesylate products
- 31722-324 Lisdexamfetamine Dimesylate 40 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 31722-326 Lisdexamfetamine Dimesylate 60 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 31722-322 Lisdexamfetamine Dimesylate 20 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 31722-321 Lisdexamfetamine Dimesylate 10 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 31722-325 Lisdexamfetamine Dimesylate 50 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 31722-323 Lisdexamfetamine Dimesylate 30 mg/1 · Tablet, Chewable · Camber Pharmaceuticals, Inc.
- 70010-214 Lisdexamfetamine Dimesylate 10 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.
- 70010-219 Lisdexamfetamine Dimesylate 60 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.
- 70010-215 Lisdexamfetamine Dimesylate 20 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.
- 70010-217 Lisdexamfetamine Dimesylate 40 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.
- 70010-216 Lisdexamfetamine Dimesylate 30 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.
- 70010-218 Lisdexamfetamine Dimesylate 50 mg/1 · Tablet, Chewable · Granules Pharmaceuticals Inc.